TG Therapeutics Announces Positive Topline Results from the ULTI
TGTX: TG Therapeutics, Inc.
2020-12-10 07:11:33
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
2020-12-10 07:11:33
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis